Key Drivers
- Strong liquidity
- Zero revenue
- Heavy cash burn
AIAI Summary
Cullinan's strategic refocus into T‑cell engagers transforms it from a long‑dated R&D story into a catalyst‑dense, binary event play—success in CLN‑978/CLN‑049 and approval/launch of zipalertinib in 2026 could materially re‑rate the stock while its ~$439M cash runway into 2029 reduces near‑term dilution risk. Treat this as a tactical, event‑driven position: monitor 2026 readouts and quarterly burn (any acceleration or capital raise would meaningfully increase downside).
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Zero revenue
- •Heavy cash burn
CGEM combines strong liquidity and low leverage with zero revenue and heavy R&D-driven cash burn that produces steep losses and negative free cash flow.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Below support
- •19% peak drop
Over the last month the price fell from $13.65 to $12.74 after a $16.30 peak on 2026-03-04, indicating a deteriorating short-term trend with resistance in the $15.0–$15.7/$15.8 zone and support near $13.65.
~19% decline from $16.30 peak to $12.74 over last month
Sentiment & News
Key News Insights:
- •2026 readout cadence
- •$439M runway
- •Insider share sales
Cullinan readies multiple 2026 clinical readouts for lead T‑cell engagers CLN‑978 and CLN‑049, backed by ~$439M cash runway into 2029, growing analyst interest, and recent insider share sales.
The forthcoming mid‑2026 data points should be the primary near‑term value drivers and could materially re‑rate the stock depending on efficacy and safety signals
Similar Companies in Healthcare
Other companies in the same sector with AI ratings